Home / Available Projects / Antibody-drug Conjugates (ADC) Against GPR20

Antibody-drug Conjugates (ADC) Against GPR20
Online Inquiry

Drug Name	GPCR-targeted Project 010
Description	G protein-coupled receptor 20 (GPR20) is an orphan GPCR. GPR20 expression is regulated by FOXF1 and ETV1 transcription factors that play critical roles in KIT-driven initiation, proliferation, and survival of gastrointestinal stromal tumor. An antibody-drug conjugate (ADC) is being developed for the treatment of gastrointestinal stromal tumor. This ADC is comprised of a monoclonal antibody that targets the GPR20 antigen and a topoisomerase I inhibitor payload. In vitro studies, the candidate showed anti-tumor activity in GPR20 expressing tumor cells.
Target	G-protein coupled receptor 20 (GPR20)
Drug Modality	Antibody-drug conjugate
Indication	Gastrointestinal stromal tumor
Product Category	Biologic
Mechanism of Action	DNA topoisomerase I inhibitors
Status	Discovery
Patent	Granted

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry